Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 121Neoplasm Metastasis 12Prostate Cancer Metastatic 4Oligometastatic Prostate Cancer 3Metastatic Hormone-sensitive Prostate Cancer (mHSPC) 3Metastatic Hormone-sensitive Prostate Cancer 3Adenocarcinoma 3Radiation Injuries 2Prostatic Diseases 2Prostate CA 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Neoplasms 2Metastatic Castration-resistant Prostate Cancer 2Urologic Diseases 1Urogenital Neoplasms 1Triple Negative Breast Neoplasms 1Stage IV Prostate Adenocarcinoma AJCC v7 1Stage I Prostate Adenocarcinoma 1Salivary Gland Neoplasms 1Recurrence 1Prostatic Neoplasms, Castration-Resistant 1Prostate Adenocarcinoma 1PSA Level Greater Than 0.03 1Oligorecurrent and Oligoprogressive Prostate Cancer Patients 1Non-metastatic, Hormone naïve Prostate Cancer 1Neoplasm Recurrence, Local 1Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) 1Metastatic Hormone-Sensitive Prostate Cance 1Metastatic Hormone Sensitive Prostate Cancer 1Metastatic Castration-sensitive Prostate Cancer 1

Interventions

Radiosurgery 1Androgen Antagonists 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Intraprostatic Prostate Cancer × Androgen Antagonists × Clear all
NCT07142967 2025-08-27

Trial Evaluating the Safety and Efficacy Of MR-Linac-Guided Radiotherapy as Salvage Treatment After External Beam Radiotherapy Recurrence (TUMORNATOR II)

NYU Langone Health

Phase NA Recruiting
28 enrolled
Genitourinary

Intraprostatic Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡